Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19

NCT04365985 is registered in ClinicalTrials.gov with Corewell Health East as lead sponsor.

NCT NCT04365985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04365985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19
Lead sponsor
Corewell Health East
Phase
Phase 2
Overall status
Terminated
Start date
April 29, 2020
Completion date
April 1, 2021
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome, coronavirus infections, covid-19, severe acute respiratory syndrome (sars)